Recent preclinical advances, including a single-dose mRNA candidate from University of Texas Medical Branch that conferred full protection against Andes hantavirus in animal models and ongoing mRNA optimization by Korea University with Moderna support, have not yet advanced to pivotal human efficacy trials. Existing licensed vaccines remain limited to certain Asian strains for hemorrhagic fever with renal syndrome and lack approval for broader hantavirus pulmonary syndrome strains or Western markets. With typical vaccine timelines requiring Phase 3 data, manufacturing scale-up, and regulatory review, trader consensus reflects the low likelihood of licensure or widespread availability by year-end 2026. An unexpected major outbreak prompting emergency use authorization could shift odds, though current surveillance and model projections do not indicate such acceleration.
สรุปจาก AI ทดลองที่อ้างอิงข้อมูลจาก Polymarket ไม่ใช่คำแนะนำในการเทรดและไม่มีผลต่อการตัดสินตลาดนี้ · อัปเดตแล้วHantavirus vaccine in 2026?
Hantavirus vaccine in 2026?
6% โอกาส
$131,789 ปริมาณ
$131,789 ปริมาณ
Dec 31, 2026
6% โอกาส
$131,789 ปริมาณ
$131,789 ปริมาณ
Dec 31, 2026
This market will resolve to "Yes" if any vaccine intended for humans and inoculating against Hantavirus (including Hantavirus Pulmonary Syndrome (HPS) or Hemorrhagic Fever with Renal Syndrome (HFRS)) receives full approval from the U.S. Food and Drug Administration between market creation and December 31, 2026, 11:59 PM ET. Otherwise, this market will resolve to "No".
The primary resolution source for this market will be official information from the FDA, including its list of approved vaccines (https://www.fda.gov/vaccines-blood-biologics/vaccines/vaccines-licensed-use-united-states), however a consensus of credible reporting may also be used.Recent preclinical advances, including a single-dose mRNA candidate from University of Texas Medical Branch that conferred full protection against Andes hantavirus in animal models and ongoing mRNA optimization by Korea University with Moderna support, have not yet advanced to pivotal human efficacy trials. Existing licensed vaccines remain limited to certain Asian strains for hemorrhagic fever with renal syndrome and lack approval for broader hantavirus pulmonary syndrome strains or Western markets. With typical vaccine timelines requiring Phase 3 data, manufacturing scale-up, and regulatory review, trader consensus reflects the low likelihood of licensure or widespread availability by year-end 2026. An unexpected major outbreak prompting emergency use authorization could shift odds, though current surveillance and model projections do not indicate such acceleration.
This market will resolve to "Yes" if any vaccine intended for humans and inoculating against Hantavirus (including Hantavirus Pulmonary Syndrome (HPS) or Hemorrhagic Fever with Renal Syndrome (HFRS)) receives full approval from the U.S. Food and Drug Administration between market creation and December 31, 2026, 11:59 PM ET. Otherwise, this market will resolve to "No".
The primary resolution source for this market will be official information from the FDA, including its list of approved vaccines (https://www.fda.gov/vaccines-blood-biologics/vaccines/vaccines-licensed-use-united-states), however a consensus of credible reporting may also be used.
The primary resolution source for this market will be official information from the FDA, including its list of approved vaccines (https://www.fda.gov/vaccines-blood-biologics/vaccines/vaccines-licensed-use-united-states), however a consensus of credible reporting may also be used.
ตลาดเปิดเมื่อ: May 4, 2026, 10:39 AM ET
ปริมาณการซื้อขาย
$131,789วันสิ้นสุด
Jan 1, 2027ตลาดเปิดเมื่อ
May 4, 2026, 10:39 AM ETผู้ตัดสินผล
0x65070BE91...This market will resolve to "Yes" if any vaccine intended for humans and inoculating against Hantavirus (including Hantavirus Pulmonary Syndrome (HPS) or Hemorrhagic Fever with Renal Syndrome (HFRS)) receives full approval from the U.S. Food and Drug Administration between market creation and December 31, 2026, 11:59 PM ET. Otherwise, this market will resolve to "No".
The primary resolution source for this market will be official information from the FDA, including its list of approved vaccines (https://www.fda.gov/vaccines-blood-biologics/vaccines/vaccines-licensed-use-united-states), however a consensus of credible reporting may also be used.Recent preclinical advances, including a single-dose mRNA candidate from University of Texas Medical Branch that conferred full protection against Andes hantavirus in animal models and ongoing mRNA optimization by Korea University with Moderna support, have not yet advanced to pivotal human efficacy trials. Existing licensed vaccines remain limited to certain Asian strains for hemorrhagic fever with renal syndrome and lack approval for broader hantavirus pulmonary syndrome strains or Western markets. With typical vaccine timelines requiring Phase 3 data, manufacturing scale-up, and regulatory review, trader consensus reflects the low likelihood of licensure or widespread availability by year-end 2026. An unexpected major outbreak prompting emergency use authorization could shift odds, though current surveillance and model projections do not indicate such acceleration.
This market will resolve to "Yes" if any vaccine intended for humans and inoculating against Hantavirus (including Hantavirus Pulmonary Syndrome (HPS) or Hemorrhagic Fever with Renal Syndrome (HFRS)) receives full approval from the U.S. Food and Drug Administration between market creation and December 31, 2026, 11:59 PM ET. Otherwise, this market will resolve to "No".
The primary resolution source for this market will be official information from the FDA, including its list of approved vaccines (https://www.fda.gov/vaccines-blood-biologics/vaccines/vaccines-licensed-use-united-states), however a consensus of credible reporting may also be used.
The primary resolution source for this market will be official information from the FDA, including its list of approved vaccines (https://www.fda.gov/vaccines-blood-biologics/vaccines/vaccines-licensed-use-united-states), however a consensus of credible reporting may also be used.
ปริมาณการซื้อขาย
$131,789วันสิ้นสุด
Jan 1, 2027ตลาดเปิดเมื่อ
May 4, 2026, 10:39 AM ETผู้ตัดสินผล
0x65070BE91...Recent preclinical advances, including a single-dose mRNA candidate from University of Texas Medical Branch that conferred full protection against Andes hantavirus in animal models and ongoing mRNA optimization by Korea University with Moderna support, have not yet advanced to pivotal human efficacy trials. Existing licensed vaccines remain limited to certain Asian strains for hemorrhagic fever with renal syndrome and lack approval for broader hantavirus pulmonary syndrome strains or Western markets. With typical vaccine timelines requiring Phase 3 data, manufacturing scale-up, and regulatory review, trader consensus reflects the low likelihood of licensure or widespread availability by year-end 2026. An unexpected major outbreak prompting emergency use authorization could shift odds, though current surveillance and model projections do not indicate such acceleration.
สรุปจาก AI ทดลองที่อ้างอิงข้อมูลจาก Polymarket ไม่ใช่คำแนะนำในการเทรดและไม่มีผลต่อการตัดสินตลาดนี้ · อัปเดตแล้ว
ระวังลิงก์ภายนอก
ระวังลิงก์ภายนอก
คำถามที่พบบ่อย